Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

Harbin Jixianglong Biotech Co., Ltd.

Has Harbin Jixianglong Biotech Co., Ltd. received an FDA warning letter? Yes. FDA issued a warning letter dated May 1, 2026 concerning products containing semaglutide and tirzepatide.

Letter facts

Letter date
May 1, 2026 (2026-05-01)
Issuing office
Center for Drug Evaluation and Research (CDER)
Recipient type
Manufacturer / API
Products named
peptide APIssemaglutide APItirzepatide APIGLP-1 receptor agonist APIs
Violation categories
MisbrandingCGMP / insanitary conditions

Understanding these violation categories

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

CGMP / insanitary conditions

FDA says it observed conditions or manufacturing practices that do not meet current good manufacturing standards, potentially risking product sterility or quality. A warning letter allows the facility to provide corrective actions.

Factual Violation Summary

FDA says the firm repackaged and relabeled externally sourced semaglutide API without quality unit procedures, documentation, process or cleaning validation, or validated analytical methods, misstating manufacturer and dates; semaglutide and tirzepatide APIs were distributed to the U.S.

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • CGMP deviations for APIs
  • quality unit oversight and traceability failures
  • drug listing and establishment registration failures (misbranding)
  • failure to validate manufacturing processes
  • inadequate cleaning validation
  • inadequate analytical method validation

More letters about Semaglutide

Recent FDA warning letters concerning Semaglutide:

Similar violations (Misbranding)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.